Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma

A review

Sylvester N. Osayi, Mark Bloomston, Carl M. Schmidt, E. Christopher Ellison, Peter Muscarella

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cancer causing death in the United States. Early tumor recurrence is an important contributor to the dismal prognosis. The availability of an accurate prognostic biomarker for predicting disease recurrence following curative resection will be beneficial for patient care. Most of the currently studied biomarkers remain in the investigational phase, with CA 19-9 being the only biomarker currently approved by the FDA. Herein, we review the utility of CA 19-9 and other investigational cellular, gene, and molecular tumor markers for predicting PDA recurrence following curative surgical resection.

Original languageEnglish (US)
Article number468959
JournalBioMed Research International
Volume2014
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Biomarkers
Adenocarcinoma
Recurrence
Tumor Biomarkers
Tumors
Neoplasms
Patient Care
Genes
Availability

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma : A review. / Osayi, Sylvester N.; Bloomston, Mark; Schmidt, Carl M.; Ellison, E. Christopher; Muscarella, Peter.

In: BioMed Research International, Vol. 2014, 468959, 2014.

Research output: Contribution to journalReview article

Osayi, Sylvester N. ; Bloomston, Mark ; Schmidt, Carl M. ; Ellison, E. Christopher ; Muscarella, Peter. / Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma : A review. In: BioMed Research International. 2014 ; Vol. 2014.
@article{0beda56f570b4a1c813bbc60833f7a8a,
title = "Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: A review",
abstract = "Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cancer causing death in the United States. Early tumor recurrence is an important contributor to the dismal prognosis. The availability of an accurate prognostic biomarker for predicting disease recurrence following curative resection will be beneficial for patient care. Most of the currently studied biomarkers remain in the investigational phase, with CA 19-9 being the only biomarker currently approved by the FDA. Herein, we review the utility of CA 19-9 and other investigational cellular, gene, and molecular tumor markers for predicting PDA recurrence following curative surgical resection.",
author = "Osayi, {Sylvester N.} and Mark Bloomston and Schmidt, {Carl M.} and Ellison, {E. Christopher} and Peter Muscarella",
year = "2014",
doi = "10.1155/2014/468959",
language = "English (US)",
volume = "2014",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma

T2 - A review

AU - Osayi, Sylvester N.

AU - Bloomston, Mark

AU - Schmidt, Carl M.

AU - Ellison, E. Christopher

AU - Muscarella, Peter

PY - 2014

Y1 - 2014

N2 - Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cancer causing death in the United States. Early tumor recurrence is an important contributor to the dismal prognosis. The availability of an accurate prognostic biomarker for predicting disease recurrence following curative resection will be beneficial for patient care. Most of the currently studied biomarkers remain in the investigational phase, with CA 19-9 being the only biomarker currently approved by the FDA. Herein, we review the utility of CA 19-9 and other investigational cellular, gene, and molecular tumor markers for predicting PDA recurrence following curative surgical resection.

AB - Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cancer causing death in the United States. Early tumor recurrence is an important contributor to the dismal prognosis. The availability of an accurate prognostic biomarker for predicting disease recurrence following curative resection will be beneficial for patient care. Most of the currently studied biomarkers remain in the investigational phase, with CA 19-9 being the only biomarker currently approved by the FDA. Herein, we review the utility of CA 19-9 and other investigational cellular, gene, and molecular tumor markers for predicting PDA recurrence following curative surgical resection.

UR - http://www.scopus.com/inward/record.url?scp=84904159265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904159265&partnerID=8YFLogxK

U2 - 10.1155/2014/468959

DO - 10.1155/2014/468959

M3 - Review article

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 468959

ER -